Chronic kidney diseases
Conditions
Interventions
Control group:Losartan potassium 100mg orally once daily.
Treatment group:On the basis of control group, Gubentongluo prescription was taken orally, once in the morning and once in the evening.
Sponsors
Seventh People’s Hospital of Shanghai University of Traditional Chinese
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Those who meet the Western medical diagnostic criteria of chronic kidney disease stage 1-3 and TCM spleen-kidney qi deficiency and blood stasis; (2) The age requirement is 18-70 years old, the gender is not limited, and the patients generally have good social compliance; (3) primary glomerulonephritis; (4) 24-hour urinary protein quantity <2.0g; (5) Informed consent, voluntary test. Those who meet the above criteria may be included in the observation cases. If the above items are "no", they are not allowed to enter the case.
Exclusion criteria
Exclusion criteria: (1) Patients with secondary CKD or more serious multiple organ injury than primary CKD; (2) In the past month, various infections have occurred, or intractable blood pressure and hyperglycemia can not be controlled by drugs; (3) The current occurrence of more severe renal anemia, acid-base balance imbalance, or water and electrolyte disorders and other major diseases; (4) Based on the basic situation analysis of this researcher, there are some diseases that reduce the possibility of enrollment and may complicate the enrollment situation, such as changes in the workplace environment and situations that easily lead to loss of contact; (5) Suspect or have a history of alcohol, drug dependence and abuse by asking medical history; (6) Those who have a sensitive constitution, such as allergic history of two or more foods or drugs, or who are informed that the drug ingredients in the study are seriously allergic; (7) Pregnant or lactating women; (8) Patients undergoing clinical trials of other drugs. Patients with "yes" in one of the above criteria are not eligible for this study and cannot participate in the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum creatinine;Serum urea nitrogen;Serum uric acid;Serum albumin; | — |
Secondary
| Measure | Time frame |
|---|---|
| 24h urinary albumin;Routine urine test;Urine Alb/Cr;Cytokines;T cell subset; | — |
Countries
China
Contacts
Public ContactJing Hu
Seventh People’s Hospital of Shanghai University of Traditional Chinese Medicine
Outcome results
None listed